NCT04520750 — Pachyonychia Congenita trial site landscape

Public-registry site landscape for NCT04520750, “VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita”, a Pachyonychia Congenita study sponsored by Palvella Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT04520750 (registry record)
Study title	VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita
Official title	VALO-2: A Multicenter, Phase 3b, Open-Label Treatment Extension Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita
Sponsor	Palvella Therapeutics, Inc.
Condition(s)	Pachyonychia Congenita
Phase	PHASE3
Listed sites	4
Site countries	United States

Patient-friendly overview of this study: eichor.com/study/NCT04520750.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT04520750 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →